| Low ASPECTS / Large Core |
| LASTE (NCT03811769) |
Thrombectomy vs medical care |
450 |
ASPECTS (CT or DWI) 0-5 if <80 years or 4-5 if ≥ 80 years; < 7h from LKW; ICA (isolated cervical occlusion excluded), M1 or M1-M2 occlusion |
180-day mRS shift analysis / 90-day mortality |
France |
Feb/2022 |
| SELECT-2 (NCT03876457) |
Thrombectomy vs medical care |
560 |
ASPECTS (CT) 3-5 and/or core volume ≥ 50 ml on CTP/DWI; < 24h from LKW; ICA or M1 occlusion |
90-day mRS shift analysis / 90-day mRS 0-2 |
USA, Canada, Australia, New Zealand and Spain |
Nov/2022 |
| TESLA (NCT03805308) |
Thrombectomy vs medical care |
300 |
ASPECTS (CT) 2-5, < 24h from LKW, ICA (cervical excluded) or M1 occlusion |
UW 90-day mRS |
USA |
Nov/2022 |
| ANGEL-ASPECT (NCT04551664) |
Thrombectomy vs medical care |
488 |
ASPECTS (CT) 3-5 or core volume 70-100 ml on CTP/DWI in patients with >6h or <6h and ASPECTS (CT) 0-2; > 24h from LKW; terminal ICA or M1 occlusion |
90-day mRS |
China |
Nov/2022 |
| TENSION (NCT03094715) |
Thrombectomy vs medical care |
665 |
ASPECTS 3-5 (CT or DWI); < 12h from LKW; M1/ICA occlusion |
90-day mRS shift analysis |
Europe and Canada |
Sep/2024 |
| Distal / medium vessel occlusion |
| DISCOUNT (NCT05030142) |
Thrombectomy vs medical care |
488 |
NIHSS ≥ 5; < 6h from LKW; primary occlusion of distal M2, M3, P1, P2, P3, A1, A2 or A3 |
90-day mRS 0-2 |
France |
Dec/2023 |
| DISTALS (NCT05152524) |
Thrombectomy vs medical care |
168 |
Perfusion lesion (CTP or MRP) ≥ 10 ml; core (CTP or DWI) ( 50% of perfusion lesion; NIHSS 4-24 or 2-24 if aphasia or hemianopia; <24h from LKW; disabling deficit; primary non-dominant M2, M3, ACA, PCA occlusion and vessel diameter ≥ 1.5 mm; not eligible for IVT |
Successful reperfusion (CTP or MRP) and no sICH |
Not informed (sponsored by a USA located company) |
Aug/2024 |
| DISTAL (NCT05029414) |
Thrombectomy vs medical care |
526 |
NIHSS ≥ 4 or disabling deficit; <6h from LKW or 6-24h from LKW if CT/CTP or DWI/FLAIR mismatch present; M2, M3-M4, A1, A2, A3, P1 or P2 occlusion |
90 day-mRS |
Switzerland |
Dec/2024 |
| ESCAPE-MeVO (NCT05151172) |
Thrombectomy vs medical care |
530 |
ASPECTS ≥ 8; NIHSS > 5 or NIHSS 3-5 with disabling deficit; <12h from LKW; M2-M3 or A2-A3 or P2-P3 occlusion; penumbra demonstrated by CTA/CT/clinical exam or CTP or MRP or DWI/MRA/clinical exam |
90-day mRS |
50 sites, coordination center at University of Calgary |
Aug/2026 |
| Vertobrobasilar occlusion |
| BAOCHE (NCT02737189) |
Thrombectomy vs medical care |
318 |
pc-ASPECTS ≥ 6; NIHSS ≥ 6; 6-24h from LKW (isolated vertigo not considered); BA or intracranial VA occlusion |
90-day mRS 0-3 |
China |
December 2022 |
| ATTENTION (NCT04751708) |
Thrombectomy vs medical care |
342 |
pc-ASPECTS ≥ 6 (≥ 8 if ≥ 80 years); NIHSS ≥ 10; <12h from estimated time of BAO |
90-day mRS 0-3 |
China |
May 2023 |
| POST-ETERNAL (NCT05105633) |
TNK 0.25 mg/kg vs tPA 0.9 mg/kg (+/- EVT) |
688 |
pc-ASPECTS ≥ 7; <24h from LKW; BA occlusion (partial or complete) |
90-day mRS 0-1 or return to baseline mRS |
Australia |
December 2026 |
| Low NIHSS with proximal occlusion |
| MOSTE (NCT03796468) |
Thrombectomy vs medical care |
824 |
ASPECTS ≥ 6; NIHSS ( 5; < 24h from LKW; ICA, M1 or M1-M2 occlusion |
90-day mortality |
France |
Feb/2022 |
| ENDOLOW (NCT04167527) |
Immediate thrombectomy vs initial medical care |
200 |
ASPECTS ≥ 6; NIHSS ( 5; < 8h from LKW; ICA, M1 or “M1-like” M2 occlusion |
90-day mRS ordinal shift analysis and sICH |
United States |
Jan/2023 |
